Late-stage biotech GID BIO wins funding from Richard King Mellon Foundation...

Late-stage biotech GID BIO wins funding from Richard King Mellon Foundation to study regenerative medicine as a potential therapeutic for severe respiratory distress Study to treat hospitalized COVID-19 patients applies...

Denver Business Journal features GID BIO...

Denver Business Journal features GID BIO: “Colorado biotech firm’s new cell therapy could eliminate the need for knee replacements” As the total number of confirmed COVID-19 cases surpasses five million...

Denver Business Journal features GID BIO: “Colorado biotech firm’s new cell therapy could eliminate the need for knee replacements”

Former Yahoo! Chairman, Wall Street Titan Roy J. Bostock Joins GID BIO as Chairman

Bostock joins late-stage biotech as pivotal Phase III trial gets underway for cellular therapy for osteoarthritis of the knee   LOUISVILLE, Colo., July 28, 2020 -- Roy J. Bostock, former Chairman...

Tulane University School of Medicine announces pivotal / Phase III clinical trial for patients with knee osteoarthritis

The Tulane University Department of Orthopedics is testing a potential cellular therapy treatment for one of the world’s most common, disabling, painful musculoskeletal conditions, osteoarthritis.  In New Orleans WWL-TV announced...

Aerospace to cellular therapy: How GID BIO’s CEO used his expansive engineering background to help design a scalable device for cellular therapy

An interview with William W. Cimino, Ph.D.   The beginning Ten years ago, the founders of GID were looking for a CEO. They made the connection between cell therapy, fat...

GID BIO addresses a growing need for cost-effective U.S. osteoarthritis treatments

The number of total knee replacement (TKR) surgeries is increasing annually, leaving experts concerned that by 2030 there may not be enough orthopedic surgeons to handle the growth. Existing alternatives...

American Journal of Sports Medicine publishes results of a clinical trial for treating osteoarthritis knee pain

Trial measures safety and efficacy of device and point-of-care cellular therapy to help reduce pain and improve function in osteoarthritic knees   Louisville, Colo., New Orleans, San Antonio, Chicago –...

An interview with William Cimino, PhD, CEO GID BIO, International Federation for Adipose Therapeutics and Science (IFATS) Annual Conference in Marseille, France

GID BIO CEO William Cimino, PhD sat down with SmartTRAK, BioMedGPS Senior Analyst, Regenerative Medicine at the International Federation for Adipose Therapeutics and Science (IFATS) Annual Conference in Marseille, France....

Physicians: advancing the future of evidence-based cellular therapy could increase quality of life for 14 million US adults suffering from knee osteoarthritis

Over the past three decades cardiothoracic procedures have significantly shifted to minimally invasive techniques with new technology, training of physicians and an ecosystem for workforce development. Orthopedics is on the...

Leaders come together for the first time to advance the field of cellular medicine and its treatment of pain and function associated with knee osteoarthritis

A first-of-its kind meeting brought leaders from eight orthopedic, sports medicine, pain management and regenerative medicine advocacy organizations together to discuss advancing cellular medicine in the U.S. The group of...

Device and cellular therapy could lead to a major development in the treatment of pain and function associated with knee osteoarthritis for 14 million US adults

Individuals who overuse their joints, such as athletes, military members and people working physically demanding jobs are at a high risk of developing knee osteoarthritis (OA), according to the Arthritis...